Trials / Completed
CompletedNCT00751738
Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)
A Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in Patients With an Implantable Cardioverter Defibrillator
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | azimilide dihydrochloride | oral, once daily until sponsor stopped the study |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2008-09-12
- Last updated
- 2017-02-01
Locations
86 sites across 7 countries: United States, Belgium, Canada, France, Germany, Poland, Spain
Source: ClinicalTrials.gov record NCT00751738. Inclusion in this directory is not an endorsement.